“ENVB has a $10 price target with a 449.45% upside”
$Enveric Biosciences(ENVB)$ shares surge as the company signs non-binding term sheets with a biotech firm for out-licensing compounds. Enveric could receive up to $200 million in milestone payments and fees if conditions are met, including IND approval and completion of testing. Royalties may range from 2.5% to 10% on future sales.
CEO Joseph Tucker expresses confidence in the partnership's potential.
ENVB has a $10 price target with a 449.45% upside, according to analysts, with no bearish recommendations and one bullish rating.
ENVB shares are up 200% at $2.50.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
